Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 20/20 | 0.58 |
| ▸ | ADRB1 | P08588 | 20/20 | 0.58 |
| ▸ | ADRB3 | P13945 | 20/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
| ▸ | HTR1A | P08908 | 2/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.58 |
| ▸ | HTR1B | P28222 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5277615 | 1.00 | ADRB2 (0.58) | ADRB2ADRB1ADRB3CYP3A4HTR1A | |
| Acetic Acid SCHEMBL5277610 | 0.90 | ADRB2 (0.73) | ADRB2ADRB1ADRB3CYP3A4HTR1A | |
| SCHEMBL6155067 | 0.89 | ADRB2 (0.71) | ADRB2ADRB1ADRB3CYP3A4HTR1A | |
| SCHEMBL5281963 | 0.89 | ADRB2 (0.71) | ADRB2ADRB1ADRB3CYP3A4HTR1A | |
| SCHEMBL5280434 | 0.88 | ADRB2 (0.51) | ADRB2ADRB1ADRB3 | |
| SCHEMBL925573 | 0.88 | ADRB2 (0.72) | ADRB2ADRB1ADRB3CYP3A4HTR1A | |
| SCHEMBL5284583 | 0.86 | ADRB2 (0.57) | ADRB2ADRB1ADRB3 | |
| SCHEMBL5292149 | 0.85 | ADRB2 (0.49) | ADRB2ADRB1ADRB3 | |
| SCHEMBL5437980 | 0.85 | ADRB2 (0.56) | ADRB2ADRB1ADRB3HTR1AHTR1B | |
| SCHEMBL5437983 | 0.85 | ADRB2 (0.56) | ADRB2ADRB1ADRB3HTR1AHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7271197-B2 | Phenethanolamine derivatives | GLAXO GROUP LIMITED (GB) | 2007-09-18 | — | — | US | disclosed |
| US-20050256201-A1 | Phenethanolamine derivatives | GLAXO GROUP LIMITED | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256201-A1 | Phenethanolamine derivatives | PNMT, PHOSPHO1, NAPEPLD | ADRB2 85/4885ADRB1 148/4885ADRB3 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.